RMOC briefing on adalimumab – December

This fifth briefing paper is provided through the RMOC system. It is the December edition of a series of briefings on best value biological medicines. The briefing summarises current aspects related to implementing best value biological medicines in the NHS. In particular, it provides an update on the procurement process.

AdalimumabBiosimilar medicineNewsRMOC medicines optimisation recommendations and resourcesRMOC recommendations and resources